ASH 2024
Find Syneos Health at Booth #1149 to discuss maximizing the value of your Oncology and Hematology assets
December 7-10, 2024
In oncology and hematology, success hinges on designing and executing trials that truly make a difference—from the start. At Syneos Health, we combine clinical innovation with deep therapeutic expertise to drive the success of your early-phase trials. As the go-to partner for early-phase oncology (EPO), we have supported over 300 EPO studies, with a dedicated team that understands the intricacies of both hematology and oncology trials.
Meet with us at ASH 2024 to explore how Syneos Health can help you implement innovative adaptive trial designs and leverage cutting-edge biostatistical methods to optimize trial outcomes.
Poster Presentation
Usage of Disease-Specific Patient Reported Outcome Measures (PROMs) for Assessing Quality of Life (QoL) in Industry Sponsored Hemophilia Interventional Trials
Daniel Mazzolenis, MD | Senior VP, Oncology & Hematology
Chris Keuker, MD | Executive Medical Director, Oncology & Hematology
Ana Baptista, MD | Senior Medical Director, Oncology & Hematology
Other Attendees
Patrick Kelly, MD | Vice President, Oncology & Hematology
Wael Harb, MD | Vice President, Oncology & Hematology
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
End-to-End Expertise in Early-Phase Oncology
Oncology Expertise at all Levels
Expertise in Nonmalignant Hematology